At a glance
ClinicalIndex Comparison RecordN/ACompleted· 50 enrolled
Drug / intervention
DESolve Cx drug eluting coronary scaffold systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Non-randomized Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System in de Novo Native Coronary Artery Lesions - DESolve Cx Single-Arm Registry
In Brief
A clinical study evaluating DESolve Cx drug eluting coronary scaffold system for Coronary Artery Disease. Completed, enrolled 50 participants across 3 sites in 2 countries.
Detailed Summary
This additional arm of the DESolve Nx study is an evaluation of the CE Mark approved DESolve Cx Novolimus Eluting Bioresorbable Scaffold System.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesBelgium, Brazil
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJan 2016
Primary CompletionJan 2017
First PostedJul 2019
Study CompletionSep 2020
TodayJul 2026
First PostedJul 26, 2019
Enrollment StartJan 20, 2016
Primary CompletionJan 22, 2017
Study CompletionSep 30, 2020
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.9 years ago
Interventions
DESolve Cx drug eluting coronary scaffold systemdevice
percutaneous coronary intervention